Viewpoints

Immune-mediated Hepatitis: Challenges in Management

Immune-mediated Hepatitis: Challenges in Management

The incidence of immune-mediated hepatitis in patients receiving immunotherapy varies based on the agent and other concomitant medications, though it is not uncommon.

Can the FDA Curb Drug Prices for Cancer Treatment?

Can the FDA Curb Drug Prices for Cancer Treatment?

The US Food and Drug Administration announced a plan to hasten generic drug approvals and thereby increase competition, potentially reducing drug prices altogether.

Feature Articles

Industry Payments to Physicians: Confronting Conflicts of Interest

Industry Payments to Physicians: Confronting Conflicts of Interest

Though imperiled by efforts to repeal the Affordable Care Act, the federal Open Payments transparency program is helping to expose industry payments to physicians.

Monoclonal Antibodies as Immunotherapy "Magic Bullets"

Monoclonal Antibodies as Immunotherapy "Magic Bullets"

Many cancers in humans are weakly immunogenic — if immunogenic at all — and overcoming this inherent property of cancer cells will be critical for the future success of cancer immunology.

Brain Cancer Resources

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters